SRD5A2 and prostate carcinoma: Also, UCSC Xena confirmed coexpression of SEMA3C with FKBP5, CYP11A1, and SRD5A2 in prostate cancer patients (https://xena.ucsc.edu) (Appendix Fig. S1c).